XI. News Releases

Major news releases during April 2012 - September 2012 are as below.

Please refer to our web site for details (http://www.takeda.com/).

Date	Summary
4-Apr-12	Open-Source Drug Research Consortium Draws a Major New Champion -- Six World Leading Drug Makers Contribute $50 Million for Early-Stage Research -- -- New Approach Speeds Drug Development by Sharing Risks --
25-Apr-12	OMONTYS® (peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United States -- Only Once-Monthly Erythropoiesis-Stimulating Agent Launched in the United States --
7-May-12	Takeda Submitted a Request for Reconsideration to the National Tax Tribunal Relating to the Correction Notice on Transfer Pricing
11-May-12	2012-2014 Mid-Range Plan -- Continuing the "Transformation into a New Takeda" that promises Sustainable Growth --
11-May-12	Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn's Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases -- Patients in the Trial Had Failed at Least One Conventional Therapy --
24-May-12	Takeda Announces the Acceptance of the European Medicines Agency Submission of Alogliptin for the Treatment of Type 2 Diabetes
28-May-12	AZILVA® Now Available for a Treatment of Hypertension in Japan
5-Jun-12	Clinical Data Presented on Orteronel (TAK-700) without Steroids in Non-metastatic Prostate Cancer
5-Jun-12	Takeda Completes Acquisition of URL Pharma, Inc. --Addition of Colcrys® (colchicine) to Takeda's Gout Treatment Portfolio Will Immediately Contribute to Company's Revenue--
8-Jun-12	Transfer of TAK-070, a Candidate Molecule for the Treatment of Alzheimer-type Dementia, to the National University Corporation
18-Jun-12	Takeda's Exclusive Distribution of Pfizer Products in Japan
20-Jun-12	Takeda Announces Acceptance of European Medicines Agency Submissions for Two Fixed-Dose Combination Therapies, Alogliptin and Pioglitazone and Alogliptin and Metformin, for the Treatment of Type 2 Diabetes
25-Jun-12	Rienso® (ferumoxytol) Receives European Marketing Authorisation for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients
29-Jun-12	Millennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma -- First oral proteasome inhibitor to enter phase 3 clinical trials --
3-Jul-12	Takeda Completes Acquisition of Brazil's Multilab -- Positions Takeda as a Top Ten Pharmaceutical Company in the World's Sixth Largest Economy --
10-Jul-12	Takeda to Price US$3 Billion Senior Note Offering
23-Jul-12	Takeda and Millennium Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe -- Proposed Indication for Use in Patients with Relapsed or Refractory CD30 Positive Hodgkin lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma --
26-Jul-12	Takeda Initiates Phase 3 Trial of Motesanib in Japan and Additional Asian Countries -- Takeda Obtains the Exclusive Worldwide Rights to Develop, Manufacture and Commercialize Motesanib --
28-Jul-12	Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone -- Resubmissions Reinforce Takeda's Confidence in These Investigational Therapies as Important Treatment Options for Millions of People Living with Type 2 Diabetes --
3-Aug-12	Agreement on Exclusive Distributorship for Sales of Johnson & Johnson's Non-prescription Drugs in Japan
9-Aug-12	Takeda and Millennium Announce Termination of Ganitumab Phase3 Study in Metastatic Pancreatic Cancer in Japan
29-Aug-12	Joint Research Agreement between the BC Cancer Agency and Takeda Pharmaceutical: Takeda to Initiate Joint Research at Shonan Incubation Laboratories
31-Aug-12	Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
5-Sep-12	Revestive® (teduglutide) Receives European Marketing Authorization for the Treatment of Adults with Short Bowel Syndrome (SBS)
12-Sep-12	Takeda Completes Its Russian Pharmaceutical Manufacturing Facility
28-Sep-12	Pronova and Takeda Announce the New Drug Application Approval for Lotriga® 2g in Japan for the Treatment of Hyperlipidemia